In light of the fact that eugenol demonstrates a concentration of anti-breast cancer properties both in vitro and in vivo, it is possible to use it to intensify the adjuvant treatment of breast cancer by targeting the E2F1/survivin pathway, particularly for the less responsive triple-negative subtype of the disease. The gene discussed is BIRC5; the disease is breast carcinoma.